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The drug retention and circulation lifetime properties of liposomal nanoparticles (LN) containing dihydrosphingomyelin (DHSM) have been
investigated. It is shown that replacement of egg sphingomyelin (ESM) by DHSM in sphingomyelin/cholesterol (Chol) (55/45; mol/mol) LN
results in substantially improved drug retention properties both in vitro and in vivo. In the case of liposomal formulations of vincristine, for
example, the half-times for drug release (T1/2) were approximately 3-fold longer for DHSM/Chol LN as compared to ESM/Chol LN, both in vitro
and in vivo. Further increases in T1/2 could be achieved by increasing the drug-to-lipid ratio of the liposomal vincristine formulations. In addition,
DHSM/Chol LN also exhibit improved circulation lifetimes in vivo as compared to ESM/Chol LN. For example, the half-time for LN clearance
(Tc1/2) at a low lipid dose (15 μmol lipid/kg, corresponding to 8 mg lipid/kg body weight) in mice was 3.8 h for ESM/Chol LN compared to 6 h for
DHSM/Chol LN. In addition, it is also shown that DHSM/Chol LN exhibit much longer half-times for vincristine release as compared to LN with
the “Stealth” lipid composition. It is anticipated that DHSM/Chol LN will prove useful as drug delivery vehicles due to their excellent drug
retention and circulation lifetime properties.
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The therapeutic benefits of liposomal nanoparticle (LN)
formulations of anticancer drugs include decreased toxicity and
increased antitumor efficacy as compared to equivalent doses of
the free drug [1–5]. Two important parameters that affect the
therapeutic benefits of LN delivery are the circulation lifetimesAbbreviations: SM, sphingomyelin; ESM, Egg sphingomyelin; DHSM,
dihydrosphingomyelin; BSM, bovine brain sphingomyelin; MSM, bovine milk
sphingomyeline; HSPC, Hydrogenated Soybean phosphatidlycholine; DSPE-
PEG2000, Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylenegly-
col)2000]; αTC, α-tocopherol; [3H]-CHE, [3H]-cholesterylhexadecyl ether;
MLV, multilamellar vesicles; LN, liposomal nanoparticle
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doi:10.1016/j.bbamem.2007.01.019of the carriers following intravenous (i.v.) injection and the rate
of drug release from the liposomes. Long circulation lifetimes
lead to enhanced accumulation of LN in disease sites such as
tumors [6,7] and slow drug release rates are of particular benefit
for cell-cycle specific drugs such as vincristine [8,9]. Extended
circulation lifetimes can be achieved using pegylated LN [10],
high lipid doses [11] or by using lipids such as sphingomyelin
[9]. Many methods have been employed to regulate drug
release, including varying the lipid composition of the LN
carrier [12], using temperature and/or pH-sensitive lipids [13–
15], increasing the drug-to-lipid ratio [16,17] and altering the
fatty acyl chain length and saturation of the lipids [18].
In previous work it has been shown that the substitution of
egg sphingomyelin for phospholipids such as distearolypho-
sphatidylcholine (DSPC) in LN results in improved drug
retention properties and longer circulation lifetime properties
[9]. It has also been shown that LN containing more saturated
PC exhibit better drug retention and longer circulation lifetimes
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work we characterize the behaviour of LN composed of
dihydrosphingomyelin (DHSM) in the anticipation that further
improvements in drug retention and circulation properties could
be achieved employing these more saturated variants of SM.
These studies employ vincristine as a representative drug that is
relatively “leaky” and difficult to retain in liposomal systems.
For example, both doxorubicin and vincristine can be readily
accumulated in LN exhibiting a pH gradient, but vincristine
leaks out much more rapidly than doxorubicin for LN with the
same lipid composition [18]. It is shown that LN containing
DHSM exhibit improved vincristine retention and longer
circulated lifetimes following intravenous injection as com-
pared to LN composed of ESM.
2. Materials and methods
2.1. Materials
Egg sphingomyelin (ESM), bovine milk sphingomyelin (MSM), hydro-
genated soybean phosphatidlycholine (HSPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[poly(ethyleneglycol)2000] (DSPE-PEG2000) were
obtained from Northern Lipids Inc.(Vancouver, BC). Bovine brain sphingo-
myelin (BSM) was purchased from Avanti Polar Lipids (Alabaster, Al, USA).
These lipids were used without further purification. Vincristine sulfate was
obtained from Fine Chemicals (Cape Town, South Africa). Cholesterol (Chol)
was obtained from Sigma (St. Louis, MO, USA) and used without further
purification. [3H]-Cholesterylhexadecyl ether (CHE) was obtained from Perkin
Elmer Life Sciences (Boston, MA, USA). [14C]-vincristine sulfate was obtained
from Chemsyn Laboratories (Lenexa, KA, USA). All other chemicals were
obtained from Sigma (St. Louis, MO, USA).
2.2. Synthesis of dihydrosphingomyelin (DHSM)
Twenty-five grams of ESMwas dissolved in 250 ml of ethanol and 2.5 g of a
10% palladium/carbon catalyst was added, the lipid and catalyst were then
placed under an argon atmosphere. The mixture was heated to 40 °C and stirred
for 2 h while hydrogen was passed through the system. Residual hydrogen was
removed with an argon flush and any active catalyst was quenched with the
addition of cyclohexane. The product was filtered through diatomaceous earth to
remove the catalyst, and then subsequently the solvent was removed.
Purification of the DHSM was accomplished by dissolving the crude product
in ethanol and adding acetone (1:1 v/v) followed by filtration, this precipitation
was repeated until the desired purity was obtained. The final product was 99%+
pure based on high performance liquid chromatography (HPLC) with NMR
analysis showed no sign of the non-hydrogenated analog.
2.3. Differential scanning calorimetry
Differential scanning calorimetry was carried out on multilamellar vesicles
(MLV) composed of the various sphingomyelins, in distilled water, with a
Calorimetry Sciences Corporation MC-DSC 4100 instrument (Lindon, UT).
Prior to loading into DSC cells, samples were brought to room temperature and
degassed for five min under vacuum with stirring. The samples were then
vortexed to ensure homogeneity and scanning with a range of 20 to 60 °C at a
scan rate of 5 °C/h was immediately carried out.
2.4. Liposome preparation
Lipids and trace amounts of [3H]-CHE were co-dissolved at appropriate
molar ratios in ethanol. MLV suspensions were generated after the addition of a
300 mM aqueous solution of magnesium sulfate for liposomes used for drug
loading or buffer composed of 20 mM HEPES, 145 mM NaCl pH 7.5 for
unloaded liposomes used in pharmacokinetic studies, yielding a final ethanolconcentration of 10% (v/v). Liposomal nanoparticles (LN) with diameters of
approximately 100 nm were generated by extrusion of MLVs through two
stacked Nuclepore polycarbonate filters with a pore size of 100 nm (10 passes)
using an extrusion device obtained from Northern Lipids (Vancouver, BC,
Canada) [19,20]. For drug loading a transmembrane ion gradient was
established through the removal of the external 300 mM magnesium sulfate
by dialysis against SEH loading buffer (300 mM sucrose, 3 mM EDTA, 20 mM
HEPES, pH 7.4). LN used in comparative pharmacokinetic studies, where no
loaded drug was necessary, were dialyzed against 20 mM HEPES, 145 mM
NaCl pH 7.5 to remove the remaining ethanol. The mean LN diameter was
determined by dynamic light scattering using a NICOMP 370 particle sizer
(Nicomp Particle Sizing Inc., Santa Barbara, CA) and found to be 106±36 nm
for ESM/Chol LN, 122±51 nm for DHSM/Chol LN and 111±47 nm for the LN
composed of HSPC/Chol/DSPE-PEG2000. Phospholipid concentrations were
determined using established techniques [21] and the specific activity of the LN
was determined using a Beckman LS3801 scintillation counter (Fullerton, CA,
USA).
2.5. Vincristine encapsulation in LN
Vincristine was encapsulated into LN using the ionophore-mediated drug
loading procedure described previously [22]. Briefly, vincristine sulfate and
trace amounts of [14C]-vincristine sulfate were added to LN (5 mM final lipid
concentration) at appropriate drug-to-lipid ratios (wt/wt), and subsequently
incubated at 65 °C prior to the addition of the calcium ionophore A23187. The
LN/drug/ionophore mixture was then incubated at 65 °C for 90 min to provide
optimal drug loading conditions. Non-encapsulated vincristine was removed
using dialysis against SEH loading buffer [22] prior to quantification of LN-
entrapped drug using dual channel counting on a Beckman LS 3801 scintillation
counter. Formulations used for in vivo studies were first dialyzed against
300 mM sucrose.
2.6. Assays for in vitro release of vincristine
In vitro drug release assays giving rise to release rates on experimentally
convenient timescales were utilized to make quantitative comparisons of drug
leakage between vincristine-loaded LN of varying drug-to-lipid ratios. In vitro
release assays for liposomal vincristine were conducted using ammonium
chloride to degrade the pH gradient [23]. Drug loaded vesicles were diluted with
release buffer (2 mM ammonium chloride, 300 mM sucrose, 20 mM HEPES,
3 mM EDTA, pH 7.4) to a lipid concentration of 1.25 mM. The diluted
liposomal drug was then placed into dialysis tubing (12–14 K M.Wt. cut off)
and dialyzed against release buffer at 50 °C. This temperature was chosen to
provide an optimal and convenient in vitro drug leakage rate, generally 50–60%
after 60 min for a drug-to-lipid ratio of 0.03(mol/mol). Leakage of vincristine
from the loaded LN was assayed by the removal of aliquots for spin column
analysis and quantification using dual label liquid scintillation counting [22,24].
The halftimes for drug release (T1/2) were calculated from exponential best fits to
the release profiles as the time at which the internal drug concentration was half
the initial concentration.
2.7. Mice
Female, 6–8 weeks old outbred ICR mice were obtained from Harlan
(Indianapolis, IN) and were used for pharmacokinetic and drug payout studies.
All mice were quarantined for at least 2 weeks prior to use and kept within a
controlled temperature (22±1 °C) and humidity (60±10%) environment.
Lighting was maintained on automatic 12 h light/dark cycles. Animal studies
were conducted in compliance with the guidelines established by the Canadian
Council on Animal Care (CCAC).
2.8. In vivo pharmacokinetics
Vincristine-loaded LN were prepared at various drug-to-lipid (D/L) ratios
and contained 300 mM sucrose as the external buffer. In most instances, drug
and lipid concentrations were adjusted to 0.2 mg/ml vincristine and 4 mg/ml
total lipid, resulting in doses of 2 mg/kg drug and 40 mg/kg lipid. Empty SM/
Table 1
Acyl chain saturation ratios, phase transition temperatures and half-life for drug
release for various sphingomyelin sources
Lipid sample Acyl chain
saturation (%) a
Tm, °C T1/2 release,
min
Bovine milk sphingomyelin 91 34.2 6.4
Bovine brain sphingomyelin 67 37.8 7.7
Egg sphingomyelin 93 40.8 28.9
Dihydrosphingomyelin 100 46 60.8
a As noted from [41].
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with higher D/L ratios to ensure that mice were injected with an equivalent total
lipid dose. Mice were injected via a lateral tail vein and, at appropriate time
points, were anesthetized (ketamine/xylazine) and blood was collected via
cardiac puncture into EDTA microtainer tubers. Blood was then centrifuged at
400×g for 15 min and plasma was collected and de-colorized for lipid and drug
determination by dual label liquid scintillation counting as described previously
[22].
To assess the pharmacokinetics of three long circulating liposomal
formulations (ESM/Chol 55/45 mol%; DHSM/Chol 55/45 mol%; HSPC/
Chol/DSPE-PEG2000 57.2/37.6/5.2 mol%), unilamellar liposomes without
loaded drug were prepared with an external buffer composed of 20 mM
HEPES, 145 mM NaCl pH 7.5. Mice were injected via a lateral tail vein at lipid
doses of either 150 μmol/kg or 15 μmol/kg and, at appropriate time points, were
anesthetized (ketamine/xylazine overdose) and blood was collected via cardiac
puncture into EDTA microtainer tubes. Blood was then centrifuged at 400×g for
15 min and plasma was collected and de-colorized for lipid determination by
liquid scintillation counting as described previously [22]. Circulation half-times
(Tc½) were calculated by fitting the plasma LN lipid levels to an exponential
function (Sigma Plot 9).
3. Results
3.1. LN containing DHSM exhibit slow drug leakage rates
The first set of experiments was aimed at characterizing the
influence of SM species on vincristine release rates from LN.
Four species of SM were employed, namely bovine milk SM
(MSM), bovine brain SM (BSM), ESM and DHSM. LN
composed of SM/Chol (55:45) were made as indicated under
Methods and loaded with vincristine to achieve a drug-to-lipid
(D/L) ratio of 0.06 (mol/mol) employing the ionophore loading
procedure. In order to achieve vincristine release rates on an
experimentally convenient timescale an in vitro release assay
consisting of incubation of drug-loaded LN in the presence of
2 mM ammonium chloride at 50 °C was employed. The
vincristine release profiles for each liposomal formulation are
shown in Fig. 1. As may be noted, LN containing either BSM or
MSM release vincristine very rapidly, with halftimes for drugFig. 1. In vitro retention of LN vincristine preparations (0.06, mol/mol) in 2 mM
ammonium chloride at 50 °C, composed of various sphingomyelin sources.
Bovine milk sphingomyelin (▾), bovine brain sphingomyelin (▴), egg
sphingomyelin (▪) and dihydrosphingomyelin (●). The lipid concentration in
the release assays was 1.25 mM total lipid. Data points represent mean drug
retention (±standard deviations) calculated from 3 samples.release (T1/2) of less than 10 min under the assay conditions
employed. LN composed of ESM/Chol exhibit improved
retention properties (T1/2 ∼29 min) whereas DHSM/Chol LN
exhibit the slowest drug payout characteristics (T1/2 ∼61 min).
Although similar T1/2 values would not be expected in vivo, it
would be expected that similar relative values would be
observed where the DHSM/Chol LN exhibit the longest
retention times. A previous study has shown that vincristine
formulations with the longest retention times observed using the
ammonium chloride release assay in vitro are also those that
exhibit the longest retention times in vivo [17].
More unsaturated lipid species usually exhibit lower gel-to-
liquid crystalline transition temperatures (Tc) values [25]. The
Tc values of the SM species employed here were determined
employing differential scanning calorimetry. As shown in
Table 1 the transition temperatures vary from 34 °C to 46 °C
for the various sphingomyelin species.
3.2. Increasing the drug-to-lipid ratio results in reduced
leakage rates in DHSM/Chol LN
The preceding results indicate that vincristine release from
DHSM/Chol LN is approximately 2 times slower than from
ESM LN. Previous studies have shown that the release rate of
vincristine from ESM/Chol LN is also highly sensitive to the
D/L ratio employed, with formulations with higher D/L values
exhibiting much slower drug release rates [16,17]. In order to
demonstrate that similar behaviour is also observed for DHSM-
containing systems, the in vitro release properties of DHSM/
Chol LN loaded to D/L ratios of 0.027 to 0.158 (mol/mol) were
compared. As shown in Fig. 2, the T1/2 for vincristine release
increased from 35 min to more than 300 min as the D/L ratio
was increased from 0.027 to 0.158 (mol/mol).
3.3. The use of DHSM and high D/L ratios results in additive
reductions in vincristine leakage in vivo
The next set of studies was aimed at delineating the in vivo
release properties of DHSM/Chol LN loaded with vincristine.
As shown in Fig. 3 for LN loaded with vincristine at a D/L ratio
of 0.034 (mol/mol) and administered to outbred ICR mice at a
drug dose level of 2 mg/kg, the substitution of DHSM for ESM
in SM/Chol LN resulted in an increase in the T1/2 for drug
release from 8.9 to 16.6 h. Similarly, increasing the D/L ratio
from 0.035 to 0.235 (mol/mol) in the DHSM formulation
resulted in an increase in T1/2 from 16.6 to 282 h (Fig. 3).
Fig. 4. Lipid recovery in plasma from circulating LN formulated of ESM/Chol
(▾) (55/45 mol%), DHSM/Chol (▴) (55/45 mol%) or stealth (▪) (HSPC/CH/
DSPE-PEG2000 57.2/37.6/5.2 mo%) liposomal formulations. Mice were dosed
at either 15 μmol/kg (Panel A) or 150 μmol/kg (Panel B), data points represent
mean lipid recovery (±standard deviations) in plasma calculated from 3 mice
each.
Fig. 2. Vincristine in vitro retention for DHSM/Chol LN preparations in 2 mM
ammonium chloride at 50 °C as determined for drug to lipid ratios (mol/mol) of
0.027(▾), 0.055 (▴), 0.099 (▪) and 0.158 (●). The lipid concentration in the
release assays was 1.25 mM total lipid. Data points represent mean drug
retention (±standard deviations) calculated from 3 samples.
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the circulation [11], empty DHSM/Chol liposomes were
included with the loaded liposomes formulated at the high D/L
ratio to achieve a constant lipid dose of 40 mg/kg for both
formulations.
3.4. DHSM/Chol LN exhibit longer circulation lifetimes than
ESM/Chol LN
In addition to drug retention properties, the circulation
lifetime of LN following i.v. administration is an important
parameter affecting the performance of liposome–drug for-
mulations. This is because long-circulating systems accumulate
more effectively at sites of disease such as tumor sites [26],
leading to improved therapeutic benefits. LN of various lipid
compositions usually exhibit dose dependent pharmacokinetics,
with rapid clearance observed at low lipid doses and muchFig. 3. Vincristine retention in circulating LN composed dihydrosphingomyelin/
cholesterol (55/45 mol%) and egg sphingomyelin/cholesterol (55/45 mol%) in
mice. Drug-to-lipid ratios (mol/mol) of LN formulations of vincristine
composed of DHSM/Chol were 0.034 (▴), 0.235 (▪) and ESM/Chol at 0.035
(▾). Mice were dosed at 71 μmol/kg (40 mg/kg) total lipid and 2.4 μmol/kg
(2 mg/kg) drug, data points represent mean drug retention (±standard deviations)
calculated from 3 mice.slower clearance at higher dose levels [27]. The gold standard
for LN with long circulation lifetimes is the so-called Stealth
formulation [28] that contains the PEG–lipid DSPE-PEG2000,
hydrogenated soy PC (HSPC) and cholesterol and exhibits in
vivo blood clearance properties that are relatively dose-
independent [29]. The circulation lifetimes of liposomes
composed of ESM/Chol (55/45 mol%), DHSM/Chol (55/45
mol%) and the “Stealth” composition (HSPC/Chol/DSPE-
PEG2000; 57.2/37.6/5.2 mol%) were therefore examined in
female ICR mice. Two lipid doses were employed. The low
lipid dose corresponded to 15 μmol phospholipid/kg (8.4 mg
lipid/kg for the SM-containing LN; 10.9 mg lipid/kg for the
“Stealth” formulation) and the high dose to 150 μmol
phospholipid/kg (84 mg lipid/kg for the SM-containing LN;Table 2
Calculated circulation half-lives (R2≥0.98) for various LN formulations
Liposome composition Tc1/2 15 μmol/kg Tc1/2 150 μmol/kg
ESM/Chol (55/45 mol%) 3.8 h 9.4 h
DHSM/Chol (55/45 mol%) 6.0 h 13.2 h
“Stealth” formulation
(HSPC/CH/DSPE-PEG2000
57.2/37.6/5.2 mo%)
10.1 h 13 h
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4 and Table 2, the DHSM/Chol LN exhibited significantly
longer Tc1/2 values than the ESM/Chol LN at both the high lipid
doses (13.2 h vs. 9.4 h) and the low lipid doses (6 h vs. 3.8 h).
The shorter Tc1/2 values observed at the lower lipid doses reflect
the dose-dependent clearance behaviour commonly observed
for LN formulations [11]. It is interesting to note that the Tc1/2
values of the DHSM/Chol LN are equivalent to the “Stealth”
formulation at the high dose levels (13.2 h vs. 13 h) and are not
markedly shorter even at the low lipid doses (6 h vs. 10.1 h).
3.5. DHSM/Chol LN exhibit significantly improved drug
retention properties compared to “Stealth” LN
It is of obvious interest to compare the drug retention
properties of “Stealth” LN and DHSM/Chol LN, particularly
given the observation that the presence of PEG-containing
lipids such as DSPE-PEG2000 in LN increases the rate of drug
release both in vitro and in vivo [30]. This effect is illustrated in
Fig. 5A, where it is shown that the presence of 5.2 mol% DSPE-
PEG2000 in ESM/Chol LN reduces the half-time for vincristine
release from 29 min to 11 min employing the in vitro release
assay where the drug release rates have been increased toFig. 5. Comparison of in vitro vincristine retention for PEGylated “stealth”
and non-PEGylated (ESM/Chol) LN in 2 mM ammonium chloride at 50 °C.
Panel A: ESM/Chol (▴) and ESM/Chol containing 5.2 mol% DSPE-PEG(2000)
(▾) at D/L ratios (mol/mol) 0.063 and 0.067 respectively. Panel B: DHSM/Chol
(▴) and a PEGylated “stealth” LN formulation (▾) at D/L ratios (mol/mol) of
0.052 and 0.05 respectively.experimentally convenient time frames by addition of 2 mM
NH4Cl. The relative release rates between DHSM/Chol LN and
“Stealth” LN are illustrated in Fig. 5B, from which it may be
calculated that DHSM/Chol LN exhibit T1/2 values for
vincristine release that are approximately 13-fold longer than
those achieved by “Stealth” LN.
4. Discussion
The results of this study indicate that DHSM is a promising
lipid for use in liposomal nanoparticle drug delivery applica-
tions due to its superior drug retention and circulation lifetime
properties. Particular areas of interest concern the reasons why
DHSM LN should exhibit such properties, the potential effects
of the increased retention on the efficacy of liposomal drug
formulations and the biocompatibility of liposomal systems
composed of DHSM.
The improved drug retention properties of DHSM as
compared to ESM indicate that the DHSM/Chol lipid bilayer
provides an improved permeability barrier as compared to that
provided by ESM/Chol bilayers. This is consistent with the fact
that, as shown here and elsewhere [31], DHSM exhibits a higher
gel-to-liquid crystalline transition temperature than ESM,
reflecting tighter intermolecular packing of DHSM as compared
to ESM. It is also consistent with the finding that DHSM
exhibits a greater affinity for cholesterol than ESM [32]. The
improvements in drug retention are significant, corresponding
to two-fold increases in the half-times for drug release for
DHSM/Chol LN loaded with vincristine as compared to ESM/
Chol LN. In this context it is interesting that substitution of
DSPC for DPPC in PC/Chol LN has little effect on vincristine
release properties [33]. DSPC has a transition temperature of
54 °C as compared to 42 °C for DPPC. This large difference in
transition temperature may be contrasted to the small difference
in transition temperature between DHSM and ESM (∼5 °C), for
which large gains in drug retention properties are observed. The
transition temperatures of component lipids are important
because, as demonstrated elsewhere [18], liposomes containing
diarachidoynoyl PC (20:0/20:0 PC) or dibehenoyl PC (22:0/
22:0 PC), which have transition temperatures of 66 °C and
75 °C respectively, are very difficult to extrude to form LN, and
LN formed from these lipids tend to aggregate extensively [18].
This contrasts with the behaviour of the DHSM-containing LN,
which are relatively straightforward to extrude and do not
exhibit significant aggregation following extrusion.
Previous work has shown that certain drugs such as
vincristine [18], vinorelbine [34] and ciprofloxacin [23] are
difficult to retain in LN. The importance of achieving slow drug
release rates is well established for vincristine, for which it has
been shown that the anti-tumor efficacy of a variety of
liposomal vincristine formulations with differing release and
clearance rates correlates strongly with the circulation half-life
of the drug in vivo [35]. This relationship indicates that, for
formulations with equivalent circulation lifetimes, the anti-
tumor efficacy increases as the half-time for drug release
increases. As a result it would be expected that a DHSM/Chol
vincristine formulation should exhibit improved efficacy
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carrier circulation lifetime and the half-time for release of the
drug are increased. It is also likely that vincristine-containing
DHSM/Chol LN will also exhibit improved anti-tumor efficacy
as compared to vincristine-containing LN with the “Stealth”
lipid composition. This is because although the circulation
lifetime may be somewhat shorter for the DHSM/Chol LN, the
retention properties of the Stealth LN are markedly less robust
as compared to the DHSM/Chol system, potentially leading to
substantially shorter drug circulation half-lives.
The improved circulation lifetime properties of DHSM/Chol
LN compared to ESM/Chol LN is consistent with the tight
packing of the DHSM/Chol lipid bilayer noted above. Previous
work has shown that the clearance rate of LN from the
circulation is critically dependent on the amount of blood
protein adsorbed to the LN surface [36]. The ability of proteins
to adsorb onto lipid bilayer membranes is, in turn, dependent
on the packing properties of the component lipids (in addition
to other factors such as surface charge) [37], where proteins
adsorb more readily to bilayers containing more unsaturated
lipids. The ability of the PEG coating on “Stealth” LN to
extend circulation lifetimes by inhibiting the binding of serum
proteins has also been noted [38]. It is also possible that
DHSM-containing LN have reduced adsorbed protein levels
compared to ESM systems due to reduced surface potentials of
DHSM membranes [31].
A final point of discussion concerns the biocompatibility of
DHSM/Chol LN, and, in particular, whether DHSM-containing
systems could elicit toxic side effects. In this regard it has been
shown that DHSM in multilamellar liposomes is readily
degraded following i.v. injection [39], although, as indicated
by the results presented here, such degradation does not result in
undue drug leakage from DHSM/Chol LN over 24 h in vivo. It
should also be noted that DHSM is a naturally occurring species
of SM. For example, over 50% of the phospholipid associated
with the human ocular lens is DHSM [40] and approximately
10% of the SM in cell plasma membranes is DHSM [41]. It is
therefore unlikely that DHSM/Chol LN should exhibit any
additional toxicity over ESM/Chol LN.
In summary the results of this investigation show that DHSM
exhibits improved properties of drug retention and circulation
lifetime following i.v. injection as compared to ESM-containing
LN. Further, DHSM/Chol LN exhibit superior drug retention
properties and comparable circulation lifetime properties as
“Stealth” LN. As a result, it is likely that DHSM/Chol LN will
be of considerable utility for the in vivo delivery of drugs that
are usually hard to retain in liposomal delivery systems.
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